The FDA has approved Lynkuet, a 60-milligram capsule therapy from Bayer, for the treatment of moderate to severe hot flashes due to menopause.
Lynkuet is the first dual neurokinin-1 and neurokinin-3 receptor antagonist approved for this indication. The once-daily, nonhormonal medication works by modulating thermoregulation through targeted receptor inhibition.
Approval was based on data from three phase 3 clinical trials — Oasis 1, 2 and 3 — involving 1,420 women, according to an Oct. 24 news release. In Oasis 1 and 2, Lynkuet met co-primary endpoints at weeks 4 and 12 by significantly reducing the frequency and severity of hot flashes among 796 participants. Oasis 3 included 627 women and assessed safety over 52 weeks.
Lynkuet is expected to be available in the U.S. in November 2025.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
